Tri-county biotech heavyweight Amgen shot up more than 8 percent July 1 on news that it had successfully defended patents on bestselling rheumatoid arthritis drug Enbrel in a court contest with competitor Sandoz. Shares of Thousand Oaks-based Amgen hit a new 52-week high and closed at $255.12. The decision by the U.S. Court of Appeals…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
